29 July 2019
Major Russian pharmaceutical company NovaMedica and the US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen®, a hormone secreted by the pineal gland in a 24-hour circadian rhythm, regulating the normal sleep/wake cycle. Production capacity expected to reach hundreds of thousands of packages per year. It will be enough to meet the requirements of patients living in the territory of the EAEU.
This is the first time Unipharm Corporation decided to localize the production of a Russian portfolio product. And for Nova Medica Innotech it is an important large long-term contract for commercial production in cooperation with an international partner.
The transfer of technology and quality control methods of Melaxen will begin immediately. Onward, after the necessary regulatory procedures, the full production cycle of the finished dosage form of the preparation will be established at the R&D center’s production facilities. Doctors and patients of the countries of the Eurasian Economic Union will have access to Russian-made Melaxen as early as 2020.
“We know how scrupulous Unipharm is about the quality of its products and how carefully it chose a partner for contract manufacturing in Russia. Therefore, we are proud that they have chosen our professionalism, flexibility and technical equipment,” - said Alexander Rudko, head of the R&D Center NovaMedica Innotech.
Unipharm Russia CEO Nikolai Anischenko stated:
“For our company, the decision to localize production is a strategic step. It fully reflects the long-term development plans, both in Russia and in the EAEU space. Our partnership with NovaMedikaInnotech will help increase modern medical care availability, help provide patients with high-quality, modern and affordable medicines, create new jobs.”
The Unipharm Group is an international group of companies established in 1992 with the purpose of providing Eurasian markets with high-quality drugs and nutritional supplements for full satisfaction of customers seeking improvement of life quality. For more than 25 years, Unipharm Group continues to provide award-winning, quality products to customers in different countries.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Enhancing spectroscopy analysis with machine learning
03 February 2025
The production of new Russian “super antibiotic” to begin in Novosibirsk
03 February 2025
A Russian company has started producing 4 veterinary vaccines
31 January 2025
The government held its first meeting on the “New technologies for preserving health” project
31 January 2025